Virus-like particle display of HER2 induces potent anti-cancer responses

References

• Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science. 2013;342:1432–3.
   PubMed Web of Science ®Google Scholar
• Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12:278–87. doi:10.1038/nrc3236. PMID:22437872.
   PubMed Web of Science ®Google Scholar
• Bianchini G, Gianni L. The immune system and response to HER2-targeted treatment in breast cancer. Lancet Oncol. 2014;15:e58–68. doi:10.1016/S1470-2045(13)70477-7. PMID:24480556.
   PubMed Web of Science ®Google Scholar
• Ménard S, Casalini P, Campiglio M, Pupa S, Agresti R, Tagliabue E. HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer. Ann Oncol. 2001;12 Suppl 1:S15–9. doi:10.1093/annonc/12.suppl_1.S15.
   PubMedGoogle Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ., Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177–82. doi:10.1126/science.3798106. PMID:3798106.
   PubMed Web of Science ®Google Scholar
• Hudis CA. Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med. 2007;357:39–51. doi:10.1056/NEJMra043186. PMID:17611206.
   PubMed Web of Science ®Google Scholar
• Sabatier R, Gonçalves A. [Pertuzumab (Perjeta®) approval in HER2-positive metastatic breast cancers]. Bull Cancer. 2014;101:765–71. PMID:25091659.
   PubMed Web of Science ®Google Scholar
• Baselga J, Carbonell X, Castañeda-Soto NJ, Clemens M, Green M, Harvey V, Morales S, Barton C, Ghahramani P. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol. 2005;23:2162–71. doi:10.1200/JCO.2005.01.014. PMID:15800309.
   PubMed Web of Science ®Google Scholar
• Garg A, Quartino A, Li J, Jin J, Wada DR, Li H, Cort??s J, McNally V, Ross G, Visich J, et al. Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors. Cancer Chemother Pharmacol. 2014;74:819–29. doi:10.1007/s00280-014-2560-3. PMID:25119184.
   PubMed Web of Science ®Google Scholar
• Leyland-Jones B. Dose scheduling–Herceptin. Oncology. 2001;61 Suppl 2:31–6. doi:10.1159/000055399.
   PubMedGoogle Scholar
• Vultaggio A, Castells MC. Hypersensitivity Reactions to Biologic Agents. Immunol Allergy Clin North Am. 2014;34:615–32. doi:10.1016/j.iac.2014.04.008. PMID:25017680.
   PubMed Web of Science ®Google Scholar
• Chung CH, Mirakhur B, Chan E, Le Q-T, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med. 2008;358:1109–17. doi:10.1056/NEJMoa074943. PMID:18337601.
   PubMed Web of Science ®Google Scholar
• Maier S, Chung CH, Morse M, Platts-Mills T, Townes L, Mukhopadhyay P, Bhagavatheeswaran P, Racenberg J, Trifan OC. A retrospective analysis of cross-reacting cetuximab IgE antibody and its association with severe infusion reactions. Cancer Med. 2015;4:36–42. doi:10.1002/cam4.333. PMID:25296628.
   PubMed Web of Science ®Google Scholar
• Castells M, Del Carmen Sancho-Serra M, Simarro M. Hypersensitivity to antineoplastic agents: Mechanisms and treatment with rapid desensitization. In: Cancer Immunology, Immunotherapy. 2012. page 1575–84.
   Web of Science ®Google Scholar
• Pondé NF, Lambertini M, de Azambuja E. Twenty years of anti-HER2 therapy-associated cardiotoxicity. ESMO Open. 2016;1:e000073. doi:10.1136/esmoopen-2016-000073. PMID:27843627.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al. Use of Chemotherapy Plus a Monoclonal Antibody Against HER2 for Metastatic Breast Cancer That Overexpresses HER2. N Engl J Med. 2001;344:783–92. doi:10.1056/NEJM200103153441101. PMID:11248153.
   PubMed Web of Science ®Google Scholar
• Baselga BJ, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, et al. Phase II Study of Weekly Intravenous Recombinant Metastatic Breast Cancer. J Clin Oncol 1996;14:737–44. doi:10.1200/JCO.1996.14.3.737. PMID:8622019.
   PubMed Web of Science ®Google Scholar
• Luque-Cabal M, García-Teijido P, Fernández-Pérez, Y, Sánchez-Lorenzo L, Palacio-Vázquez I. Mechanisms behind the resistance to trastuzumab in HER2-amplified breast cancer and strategies to overcome It. Clin Med Insights Oncol. 2016;10:21–30. PMID:27042153.
   PubMed Web of Science ®Google Scholar
• Farkas AM, Finn OJ. Vaccines based on abnormal self-antigens as tumor-associated antigens: Immune regulation. Semin. Immunol. 2010;22:125–31. doi:10.1016/j.smim.2010.03.003. PMID:20403708.
   PubMed Web of Science ®Google Scholar
• Ladjemi MZ, Jacot W, Chardès T, Pèlegrin A, Navarro-Teulon I. Anti-HER2 vaccines: New prospects for breast cancer therapy. Cancer Immunol. Immunother. 2010;59:1295–312. doi:10.1007/s00262-010-0869-2. PMID:20532501.
   PubMed Web of Science ®Google Scholar
• Baxevanis CN, Voutsas IF, Gritzapis AD, Perez SA, Papamichail M. HER-2/neu as a target for cancer vaccines. Futur Med. 2010;2:213–26.
   Web of Science ®Google Scholar
• Jensen-Jarolim E, Singer J. Cancer vaccines inducing antibody production: more pros than cons. Expert Rev Vaccines. 2011;10:1281–9. doi:10.1586/erv.11.105. PMID:21919618.
   PubMed Web of Science ®Google Scholar
• Schijns VEJC. Immunopotentiators in Modern Vaccines. second edition. The Netherlands: Elsevier;2017
   Google Scholar
• Nurieva RI, Liu X, Dong C. Molecular mechanisms of T-cell tolerance. Immunol. Rev. 2011;241:133–44. doi:10.1111/j.1600-065X.2011.01012.x. PMID:21488895.
   PubMed Web of Science ®Google Scholar
• Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science. 2003;301:1374–7. doi:10.1126/science.1086907. PMID:12920303.
   PubMed Web of Science ®Google Scholar
• Allen CDC, Okada T, Tang HL, Cyster JG. Imaging of germinal center selection events during affinity maturation. Science. 2007;315:528–31. doi:10.1126/science.1136736. PMID:17185562.
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol. 2010;10:787–96. doi:10.1038/nri2868. PMID:20948547.
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Rohrer UH, Kündig TM, Bürki K, Hengartner H, Zinkernagel RM. The influence of antigen organization on B cell responsiveness. Science. 1993;262:1448–51. doi:10.1126/science.8248784. PMID:8248784.
   PubMed Web of Science ®Google Scholar
• Chackerian B, Durfee MR, Schiller JT. Virus-Like Display of a Neo-Self Antigen Reverses B Cell Anergy in a B Cell Receptor Transgenic Mouse Model. J Immunol. 2008;180:5816–25. doi:10.4049/jimmunol.180.9.5816. PMID:18424700.
   PubMed Web of Science ®Google Scholar
• Chackerian B, Frietze KM. Moving towards a new class of vaccines for non-infectious chronic diseases. Expert Rev Vaccines. 2016;15:561–3. doi:10.1586/14760584.2016.1159136. PMID:26919571.
   PubMed Web of Science ®Google Scholar
• Thrane S, Janitzek CM, Matondo S, Resende M, Gustavsson T, de Jongh WA, Clemmensen S, Roeffen W, van de Vegte-Bolmer M, van Gemert GJ, et al. Bacterial superglue enables easy development of efficient virus-like particle based vaccines. J Nanobiotechnology. 2016;14:30. doi:10.1186/s12951-016-0181-1. PMID:27117585.
   PubMed Web of Science ®Google Scholar
• Zakeri B, Fierer JO, Celik E, Chittock EC, Schwarz-Linek U, Moy VT, Howarth M. Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin. Proc Natl Acad Sci U S A. 2012;109:E690–7. doi:10.1073/pnas.1115485109. PMID:22366317.
   PubMed Web of Science ®Google Scholar
• Kwong KY, Hung MC. A novel splice variant of HER2 with increased transformation activity. Mol Carcinog. 1998;23:62–8. doi:10.1002/(SICI)1098-2744(199810)23:2%3c62::AID-MC2%3e3.0.CO;2-O. PMID:9808159.
   PubMed Web of Science ®Google Scholar
• Castiglioni F, Tagliabue E, Campiglio M, Pupa SM, Balsari A, Ménard S. Role of exon-16-deleted HER2 in breast carcinomas. Endocr Relat Cancer. 2006;13:221–32. doi:10.1677/erc.1.01047. PMID:16601290.
   PubMed Web of Science ®Google Scholar
• Castagnoli L, Iezzi M, Ghedini GC, Ciravolo V, Marzano G, Lamolinara A, Zappasodi R, Gasparini P, Campiglio M, Amici A, et al. Activated d16HER2 homodimers and src kinase mediate optimal efficacy for trastuzumab. Cancer Res. 2014;74:6248–59. doi:10.1158/0008-5472.CAN-14-0983. PMID:25164009.
   PubMed Web of Science ®Google Scholar
• Lollini P-L, Cavallo F, De Giovanni C, Nanni P. Preclinical vaccines against mammary carcinoma. Expert Rev Vaccines. 2013;12:1449–63. doi:10.1586/14760584.2013.845530. PMID:24195482.
   PubMed Web of Science ®Google Scholar
• De Giovanni C, Nicoletti G, Quaglino E, Landuzzi L, Palladini A, Ianzano ML, Dall'Ora M, Grosso V, Ranieri D, Laranga R, et al. Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2. Breast Cancer Res. 2014;16:R10. doi:10.1186/bcr3602. PMID:24451168.
   PubMed Web of Science ®Google Scholar
• Palladini A, Nicoletti G, Lamolinara A, Dall'Ora M, Balboni T, Ianzano ML, Laranga R, Landuzzi L, Giusti V, Ceccarelli C, et al. HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response. Oncotarget. 2017;8:54444–58. doi:10.18632/oncotarget.17088. PMID:28903354.
   PubMed Web of Science ®Google Scholar
• Stahl PD, Ezekowitz R a. The mannose receptor is a pattern recognition receptor involved in host defense. Curr Opin Immunol 1998;10:50–5. doi:10.1016/S0952-7915(98)80031-9. PMID:9523111.
   PubMed Web of Science ®Google Scholar
• Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA, Arteaga CL. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res. 2007;13:4909–19. doi:10.1158/1078-0432.CCR-07-0701. PMID:17699871.
   PubMed Web of Science ®Google Scholar
• Curigliano G, Romieu G, Campone M, Dorval T, Duck L, Canon J-L, Roemer-Becuwe C, Roselli M, Neciosup S, Burny W, et al. A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2016;156:301–10. doi:10.1007/s10549-016-3750-y. PMID:26975189.
   PubMed Web of Science ®Google Scholar
• Marmé F. Immunotherapy in Breast Cancer. Oncol. Res Treat. 2016;39:335–45. doi:10.1159/000446340.
   PubMed Web of Science ®Google Scholar
• Jennings GT, Bachmann MF. Immunodrugs: Therapeutic VLP-Based Vaccines for Chronic Diseases. Annu Rev Pharmacol Toxicol. 2009;49:243–63. doi:10.1146/annurev-pharmtox-061008-103129. PMID:18851683.
   PubMed Web of Science ®Google Scholar
• Chackerian B. Virus-like particles: flexible platforms for vaccine development. Expert Rev Vaccines. 2007;6:381–90. doi:10.1586/14760584.6.3.381. PMID:17542753.
   PubMed Web of Science ®Google Scholar
• Sallusto F. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 1995;182:389–400. doi:10.1084/jem.182.2.389. PMID:7629501.
   PubMed Web of Science ®Google Scholar
• Diebold SS, Plank C, Cotten M, Wagner E, Zenke M. Mannose receptor-mediated gene delivery into antigen presenting dendritic cells. Somat Cell Mol. Genet. 2002;27:65–74. doi:10.1023/A:1022975705406. PMID:12774941.
   PubMedGoogle Scholar
• Al-Barwani F, Young SL, Baird MA, Larsen DS, Ward VK. Mannosylation of virus-like particles enhances internalization by antigen presenting cells. PLoS One. 2014;9. doi:10.1371/journal.pone.0104523.
   PubMed Web of Science ®Google Scholar
• Nanni P, Landuzzi L, Nicoletti G, De Giovanni C, Rossi I, Croci S, Astolfi A, Iezzi M, Di Carlo E, Musiani P, et al. Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent. J Immunol. 2004;173:2288–96. doi:10.4049/jimmunol.173.4.2288. PMID:15294941.
   PubMed Web of Science ®Google Scholar
• Palladini A, Nicoletti G, Pappalardo F, Murgo A, Grosso V, Stivani V, Ianzano ML, Antognoli A, Croci S, Landuzzi L, et al. In silico modeling and in vivo efficacy of cancer-preventive vaccinations. Cancer Res. 2010;70:7755–63. doi:10.1158/0008-5472.CAN-10-0701. PMID:20924100.
   PubMed Web of Science ®Google Scholar
• Iezzi M, Quaglino E, Amici A, Lollini P-L, Forni G, Cavallo F. DNA vaccination against oncoantigens: A promise. Oncoimmunology. 2012;1:316–25. doi:10.4161/onci.19127. PMID:22737607.
   PubMed Web of Science ®Google Scholar
• Corteś J, Fumoleau P, Bianchi GV, Petrella TM, Gelmon K, Pivot X, Verma S, Albanell J, Conte P, Lluch A, et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: Activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012;30:1594–600. doi:10.1200/JCO.2011.37.4207. PMID:22393084.
   PubMed Web of Science ®Google Scholar
• Longva KE, Pedersen NM, Haslekås C, Stang E, Madshus IH. Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. Int J Cancer. 2005;116:359–67. doi:10.1002/ijc.21015. PMID:15800944.
   PubMed Web of Science ®Google Scholar
• Hommelgaard AM. Association with Membrane Protrusions Makes ErbB2 an Internalization-resistant Receptor. Mol Biol Cell. 2004;15:1557–67. doi:10.1091/mbc.E03-08-0596. PMID:14742716.
   PubMed Web of Science ®Google Scholar
• Austin CD, De Mazière AM, Pisacane PI, van Dijk SM, Eigenbrot C, Sliwkowski MX, Klumperman J, Scheller RH. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell. 2004;15:5268–82. doi:10.1091/mbc.E04-07-0591. PMID:15385631.
   PubMed Web of Science ®Google Scholar
• Clay TM, Osada T, Hartman ZC, Hobeika A, Devi G, Morse MA, Kim Lyerly H. Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines. Immunol Res. 2011;49:235–47. doi:10.1007/s12026-010-8186-6. PMID:21136201.
   PubMed Web of Science ®Google Scholar
• Triulzi C, Vertuani S, Curcio C, Antognoli A, Seibt J, Akusjärvi G, Wei WZ, Cavallo F, Kiessling R. Antibody-dependent natural killer cell-mediated cytotoxicity engendered by a kinase-inactive human HER2 adenovirus-based vaccination mediates resistance to breast tumors. Cancer Res. 2010;70:7431–41. doi:10.1158/0008-5472.CAN-10-0493. PMID:20823150.
   PubMed Web of Science ®Google Scholar
• Disis ML, Wallace DR, Gooley TA, Dang Y, Slota M, Lu H, Coveler AL, Childs JS, Higgins DM, Fintak PA, et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol. 2009;27:4685–92. doi:10.1200/JCO.2008.20.6789. PMID:19720923.
   PubMed Web of Science ®Google Scholar
• Chen G, Gupta R, Petrik S, Laiko M, Leatherman JM, Asquith JM, Daphtary MM, Garrett-Mayer E, Davidson NE, Hirt K, et al. A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF-Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast Cancer. Cancer Immunol Res. 2014;2:949–61. doi:10.1158/2326-6066.CIR-14-0058. PMID:25116755.
   PubMed Web of Science ®Google Scholar
• Limentani SA, Csampone M, Dorval T, Curigliano G, de Boer R, Vogel C, White S, Bachelot T, Canon JL, Disis M, et al. A non-randomized dose-escalation phase i trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors. Breast Cancer Res Treat. 2016;156:319–30. doi:10.1007/s10549-016-3751-x. PMID:26993131.
   PubMed Web of Science ®Google Scholar
• Quaglino E, Mastini C, Amici A, Marchini C, lezzi M, Lanzardo S, De Giovanni C, Montani M, Lollini PL, Masucci G, et al. A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins. Cancer Res. 2010;70:2604–12. doi:10.1158/0008-5472.CAN-09-2548. PMID:20332241.
   PubMed Web of Science ®Google Scholar
• De Giovanni C, Nicoletti G, Palladini A, Croci S, Landuzzi L, Antognoli A, Murgo A, Astolfi A, Ferrini S, Fabbi M, et al. A multi-DNA preventive vaccine for p53/Neu-driven cancer syndrome. Hum Gene Ther. 2009;20:453–64. doi:10.1089/hum.2008.172. PMID:19215191.
   PubMed Web of Science ®Google Scholar
• Finkle D, Quan ZR, Asghari V, Kloss J, Ghaboosi N, Mai E, Wong WL, Hollingshead P, Schwall R, Koeppen H, et al. HER2-Targeted Therapy Reduces Incidence and Progression of Midlife Mammary Tumors in Female Murine Mammary Tumor Virus huHER2-Transgenic Mice. Clin Cancer Res. 2004;10:2499–511. doi:10.1158/1078-0432.CCR-03-0448. PMID:15073130.
   PubMed Web of Science ®Google Scholar
• Marchini C, Gabrielli F, Iezzi M, Zenobi S, Montani M, Pietrella L, Kalogris C, Rossini A, Ciravolo V, Castagnoli L, et al. The human splice variant Δ16HER2 induces rapid tumor onset in a reporter transgenic mouse. PLoS One. 2011;6:1–7. doi:10.1371/journal.pone.0018727.
   Web of Science ®Google Scholar
• Croci S, Nanni P, Palladini A, Nicoletti G, Grosso V, Benegiamo G, Landuzzi L, Lamolinara A, Ianzano ML, Ranieri D, et al. Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis. Breast Cancer Res. 2015;17:70. doi:10.1186/s13058-015-0588-x. PMID:25997501.
   PubMed Web of Science ®Google Scholar